Drug intelligence / Profile preview

Silankang

Development stage: Unknown
Lead developer: Hangzhou Grand Biologic Pharmaceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Silankang is a live biotherapeutic product (LBP) consisting of a combination of four probiotic strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. Developed by Hangzhou Yuanda Biopharmaceutical, it is formulated as a live bacterial preparation designed to restore the ecological balance of the intestinal microbiota. The mechanism of action involves the replenishment of beneficial anaerobic and facultative anaerobic bacteria that produce organic acids and bacteriocins to inhibit the growth of pathogenic organisms. *Bacillus cereus* specifically acts by consuming oxygen in the intestinal tract, thereby creating an anaerobic environment that facilitates the colonization and growth of *Bifidobacterium* and other beneficial species. Silankang is primarily indicated for gastrointestinal disorders associated with intestinal dysbiosis, including diarrhea and constipation, and is currently undergoing Phase II/III clinical evaluation in China for the treatment of functional constipation during pregnancy.

Brand names: Silankang
Other names: Quadruple Live Bacteria TabletsCombined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus tablets (live)

Beyond the preview

Go deeper on Silankang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Silankang.

Explore the full profile